

# Resource Summary Report

Generated by [NIF](#) on Aug 26, 2026

## DU145

RRID:CVCL\_0105

Type: Cell Line

### Proper Citation

RRID:CVCL\_0105

### Cell Line Information

**URL:** [https://web.expasy.org/cellosaurus/CVCL\\_0105](https://web.expasy.org/cellosaurus/CVCL_0105)

**Proper Citation:** RRID:CVCL\_0105

**Description:** Cell line DU145 is a Cancer cell line with a species of origin Homo sapiens (Human)

**Sex:** Male

**Disease:** Prostate carcinoma

**Defining Citation:** [PMID:631930](#), [PMID:1574572](#), [PMID:1873816](#), [PMID:2744886](#), [PMID:3335022](#), [PMID:3518877](#), [PMID:6244232](#), [PMID:6935474](#), [PMID:7017212](#), [PMID:8104329](#), [PMID:8510267](#), [PMID:8612713](#), [PMID:9018337](#), [PMID:9214606](#), [PMID:9331090](#), [PMID:9460501](#), [PMID:10700174](#), [PMID:10702678](#), [PMID:10972993](#), [PMID:11135431](#), [PMID:11172901](#), [PMID:11280753](#), [PMID:11304728](#), [PMID:11414198](#), [PMID:11416159](#), [PMID:12606952](#), [PMID:12615715](#), [PMID:12725112](#), [PMID:14518029](#), [PMID:15486987](#), [PMID:15748285](#), [PMID:17088437](#), [PMID:17254797](#), [PMID:17440963](#), [PMID:19372543](#), [PMID:20164919](#), [PMID:22068913](#), [PMID:22275356](#), [PMID:22336246](#), [PMID:22347499](#), [PMID:22384151](#), [PMID:22460905](#), [PMID:22628656](#), [PMID:23671654](#), [PMID:23856246](#), [PMID:23933261](#), [PMID:23957452](#), [PMID:24279929](#), [PMID:24670534](#), [PMID:25485619](#), [PMID:25877200](#), [PMID:26589293](#), [PMID:26972028](#), [PMID:27141528](#), [PMID:27377824](#), [PMID:27397505](#), [PMID:27807467](#), [PMID:28196595](#), [PMID:30244336](#), [PMID:30629668](#), [PMID:30787054](#), [PMID:30894373](#), [PMID:30971826](#), [PMID:31068700](#), [PMID:31395879](#), [PMID:31733513](#), [PMID:31978347](#), [PMID:35839778](#), [PMID:38861359](#), [PMID:38892296](#)

**Comments:** Population: Caucasian., Part of: TCGA-110-CL cell line panel., Part of: NCI-60 cancer cell line panel., Part of: MD Anderson Cell Lines Project., Part of: JFCR39 cancer cell line panel., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

**Category:** Cancer cell line

**Organism:** Homo sapiens (Human)

**Name:** DU145

**Synonyms:** DU-145, Du-145, DU 145, DU\_145, DU.145, Duke University 145

**Cross References:** BTO:BTO\_0001332, CLO:CLO\_0002840, CLO:CLO\_0051536, EFO:EFO\_0005441, MCCL:MCC:0000140, CLDB:cl1108, CLDB:cl1109, CLDB:cl4961, CLDB:cl5184, AddexBio:C0019004/4984, ArrayExpress:E-MTAB-783, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, ATCC:HTB-81, BCRC:60348, BCRJ:0078, BioGRID\_ORCS\_Cell\_line:860, BioSample:SAMN03472017, BioSample:SAMN03472041, BioSample:SAMN03472757, BioSample:SAMN05292468, BioSample:SAMN10988253, cancercellines:CVCL\_0105, CCRID:1101HUM-PUMC000006, CCRID:3101HUMSCSP5024, CCRID:3101HUMTCHu222, Cell\_Model\_Passport:SIDM00120, ChEMBL-Cells:ChEMBL3308034, ChEMBL-Targets:ChEMBL613508, CLS:300168, Cosmic:688116, Cosmic:699306, Cosmic:704850, Cosmic:721367, Cosmic:721558, Cosmic:755299, Cosmic:759893, Cosmic:801349, Cosmic:809223, Cosmic:809224, Cosmic:850415, Cosmic:850824, Cosmic:869156, Cosmic:875891, Cosmic:876395, Cosmic:897454, Cosmic:905935, Cosmic:911998, Cosmic:918501, Cosmic:921050, Cosmic:922550, Cosmic:923401, Cosmic:923956, Cosmic:943177, Cosmic:948075, Cosmic:949247, Cosmic:974300, Cosmic:1028649, Cosmic:1028700, Cosmic:1057758, Cosmic:1070887, Cosmic:1071478, Cosmic:1071905, Cosmic:1075274, Cosmic:1092597, Cosmic:1172627, Cosmic:1175887, Cosmic:1176617, Cosmic:1212490, Cosmic:1218869, Cosmic:1305381, Cosmic:1312368, Cosmic:1330912, Cosmic:1436047, Cosmic:1481419, Cosmic:1542078, Cosmic:1689715, Cosmic:1712065, Cosmic:1995389, Cosmic:1998439, Cosmic:2580127, Cosmic:2585152, Cosmic:2585229, Cosmic:2592487, Cosmic:2651768, Cosmic:2669167, Cosmic:2674179, Cosmic:2816220, Cosmic-CLP:905935, DepMap:ACH-000979, DSMZ:ACC-261, DSMZCellDive:ACC-261, EGA:EGAS00001000610, EGA:EGAS00001000978, ENCODE:ENCBS077VSE, ENCODE:ENCBS721QHV, FANTOM5\_SSTAR:10490-107B4, GDSC:905935, GEO:GSM2120, GEO:GSM50224, GEO:GSM50288, GEO:GSM91924, GEO:GSM142455, GEO:GSM142456, GEO:GSM482671, GEO:GSM525794, GEO:GSM648818, GEO:GSM648819, GEO:GSM743479, GEO:GSM750774, GEO:GSM750834, GEO:GSM784791, GEO:GSM799369, GEO:GSM799379, GEO:GSM799432, GEO:GSM799442, GEO:GSM843494, GEO:GSM886988, GEO:GSM888057, GEO:GSM1153440, GEO:GSM1153441, GEO:GSM1181273, GEO:GSM1181302, GEO:GSM1181306, GEO:GSM1181328, GEO:GSM1374469, GEO:GSM1374470, GEO:GSM1669745, GEO:GSM2124639, IARC\_TP53:751, ICLC:HTL99013, IZSLER:BS TCL 141, KCB:KCB 200701YJ, KCLB:30081, LiGeA:CCLE\_356, LINCS\_LDP:LCL-1146, Lonza:761, NCBI\_Iran:C428, NCI-DTP:DU-145, Pharmacodb:DU145\_309\_2019, PRIDE:PXD003105, PRIDE:PXD003539, PRIDE:PXD005942, PRIDE:PXD005946, PRIDE:PXD030304, Progenetix:CVCL\_0105, PubChem\_Cell\_line:CVCL\_0105, RCB:RCB2143, SKY/M-FISH/CGH:2792, TKG:TKG 0604, TOKU-E:1103, Wikidata:Q5206280

**ID:** CVCL\_0105

**Record Creation Time:** 20220427T215824+0000

**Record Last Update:** 20260815T232722+0000

No rating or validation information has been found for DU145.

No alerts have been found for DU145.

---

## Data and Source Information

**Source:** [Cellosaurus](#)

---

## Usage and Citation Metrics

We found 4400 mentions in open access literature.

**Listed below are recent publications.** The full list is available at [NIF](#) .

Takano K, et al. (2026) DS-3939a: A TA-MUC1-Directed Antibody-Drug Conjugate with Broad Antitumor Activity. *Molecular cancer therapeutics*, 25(1), 7.

Kim SH, et al. (2026) Synthesis of Bispecific Conjugates by ADP-Ribosyl Cyclases. *Advanced science (Weinheim, Baden-Wurtemberg, Germany)*, 13(13), e18329.

Kim M, et al. (2026) Bone Metastatic Progression of Prostate Cancer Is Regulated by TRIM28-LDHA-Mediated Metabolism. *Molecular cancer research : MCR*, 24(2), 93.

Huang KH, et al. (2026) TG-interacting factor 1 mediates TNF-induced Ccl2 expression in adipocytes to promote prostate cancer progression. *FEBS letters*, 600(13), 1885.

Kalla J, et al. (2026) Biobank of genetically defined murine prostate cancer tumoroids uncovers oncogenic pathways and drug vulnerabilities driven by PTEN-loss. *Cell reports methods*, 6(4), 101370.

Liu SS, et al. (2026) Epigenetic regulation of NDGA and its synergistic inhibition with EZH2 inhibitors in prostate cancer via NRP1. *Acta pharmacologica Sinica*, 47(6), 1643.

Riegerov?? P, et al. (2026) Laurdan: Clarifying Photophysics and Advancing the Characterization of Extracellular Vesicles. *Chemphyschem : a European journal of chemical physics and physical chemistry*, 27(5), e202500800.

Ding J, et al. (2026) CDC20 promotes prostate cancer progression via modulating c-MYC and PI3K-AKT signaling. *iScience*, 29(7), 116409.

Hu X, et al. (2026) Immune gene diversity and STING1 variants in shaping cancer immunity across different genetic ancestry populations. *Cell reports*, 45(2), 116882.

Chen F, et al. (2026) Three-Dimensional Tumor Spheroids Reveal B7-H3 CAR T Cell Infiltration Dynamics and Microenvironment-Induced Functional Reprogramming in Solid Tumors. *Cells*, 15(2).

Cunningham ML, et al. (2026) PARP inhibitors elicit distinct transcriptional programs in homologous recombination competent castration-resistant prostate cancer. *Molecular oncology*, 20(2), 369.

He H, et al. (2026) An Artificial Antibody-Based Toolbox Accelerates Validation of Hidden Microproteins Encoded by the Dark Genome. *Advanced science* (Weinheim, Baden-Wurttemberg, Germany), 13(28), e15707.

Ciummo SL, et al. (2026) Prostatic fibroblast reprogramming by Interleukin-30 activates prostate cancer metastasis programs. *Molecular biomedicine*, 7(1).

Alhourani F, et al. (2026) Targeting SUV4-20H Epigenetic Enzymes Enhances Topoisomerase II Poisoning in Prostate Cancer. *Cancer research*, 86(1), 236.

Fu H, et al. (2026) A smart gene circuit for precise regulation of tumor cell behavior. *Synthetic and systems biotechnology*, 11, 237.

Ji Y, et al. (2026) Serotonin Modulates Lineage Plasticity in Neuroendocrine Prostate Cancer via Epigenetic Reprogramming. *Cancer discovery*, 16(4), 760.

Jakobsen JS, et al. (2026) Sym024 Interacts with a Unique Epitope on the CD73 Homodimer, Favoring Effective Bivalent Binding to Improve Anti-PD-1 Therapy. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 32(6), 1120.

Gangarossa G, et al. (2026) Non-Enzymatic Isolation of Cancer-Associated Fibroblasts From Human Prostate Tumor Explants. *Bio-protocol*, 16(5), e5614.

K??cher S, et al. (2026) Overexpression of the ERG oncogene in prostate cancer identifies candidates for PARP inhibitor-based radiosensitization. *The Journal of clinical investigation*, 136(6).

Purohit TA, et al. (2026) Genetic loss of CHD1 regulates distinct histone post-translational modifications in the development of castration-resistant prostate cancer. *Neoplasia* (New York, N.Y.), 73, 101289.